Alcon has abruptly taken its Cypass microstent off the global market due to problems with the five-year safety data. It found that endothelial cell loss (ECL) was greater with the microstent than in the cataract surgery-only control group. In the eye, these cells sit in the inner layer of the cornea to keep it dry and are crucial for maintaining fluid buildup and visual acuity.